Introduction
Theta rhythms of the hippocampus are proposed to be essential for learning and memory [1]. Until recently, theta oscillations between frequencies of 2 and 12 Hz were thought to be generated primarily by the entorhinal input, CA3 Schaffer collaterals and voltage dependent Ca2+ currents in pyramidal cells [2]. However, recent findings showed that besides the inputs from multiple brain areas, intrinsic theta oscillators within the hippocampus are critical for theta rhythm generation [3]. A main contributor for theta generation and modulation is the medial septum and diagonal band of Broca (MS-DBB), another important input to the hippocampus[4]. The MS-DBB contains cholinergic, GABAergic, and glutamatergic neurons directly projecting the hippocampus [4,5]. It has been suggested that a fine interplay exists between the external inputs regulating the modulation of the amplitude (power) and frequency in hippocampal theta rhythms [5,6]. Although it remains mechanistically unclear how network activity relates to memory, it has been suggested that the changes in theta frequency and power participate and promote in the synchronization of hippocampal activity, and this phenomena could partially explain the mechanism behind memory formation and consolidation [7]. In this regard, such changes in oscillatory theta activity are primarily dependent on cholinergic afferents originating in the MS-DBB [8]. For example, in anesthetized and freely moving mice, it was found that stimulation of cholinergic neurons enhances theta rhythm and suppresses peri-theta frequency bands, therefore increasing both power and coherence of theta oscillations [8]. In this vein, the role of the pedunculopontine tegmental nucleus (PPN) was evaluated due to its cholinergic component. In the present study, it was found that the PPN opioid system can enhance or suppress the carbachol (a cholinergic agonist) induced hippocampal theta activity depending on the actual level of PPN activation [9]. This data suggests that the potential role of cholinergic activation relays in synchronizing hippocampal activity [9].
Aiming to further study this hypothesis, by using the technique of intraseptal microinfusion of carbachol, total power increase in the theta band was found [4]. Overall, it is clear that hippocampal theta activity induced by the cholinergic agonist i.e. carbachol, contributes to enhancing power and in less proportion, synchronization of the hippocampal theta activity; however, all of the previous experiments have been performed in utilizing the in-vivo experimental approach. This particular brings the issue of keeping cholinergic inputs from multiple brain areas and therefore making difficult to dissect the specific contribution of septo-cholinergic neurons projecting directly to the hippocampus. Aiming to overcome this problem we explored the effect of the cholinergic agonist carbachol in the complete septo-hippocampal preparation [3]. The preparation is capable of self generating hippocampal activity in the theta frequency band (2 - 10 Hz) and most importantly, comprises the medial septum with all the afferents connected to the hippocampus, including all the septo-hippocampal cholinergic circuitry [3]. Here, we demonstrated that carbachol in a dose dependent manner influences the power of hippocampal theta activity; therefore, suggesting that the main effect of septo-cholinergic neurons relays in theta power modulation.
Materials and methods
All procedures were performed according to protocols and guidelines approved by the UNAM University Animal Care Committee. Mice (P30-P35) were decapitated, the brain was rapidly removed, and placed in ice-cold high sucrose artificial CSF (ACSF) solution (in mM: 252 sucrose, 3 KCl, 2MgSO4 24 NaHCO3, 1.25 NaH2PO4, 1.2 CaCl2, and 10 glucose) and bubbled with carbogen (95% O2 and 5% CO2). The cerebellum and frontal cortex were removed with a razor blade, and the hemispheres were separated and allowed to recover for 2 - 3 min in the oxygenated sucrose solution. Hippocampal isolate was then removed from the remaining hemisection as described previously [3].
After dissection, the hippocampal complex was left at room temperature in ACSF and bubbled with carbogen for 60 min. For recording, the preparation was transferred quickly to a custom-made submerged recording chamber. Recordings were performed at 30 - 32 °C after an additional 30 min period acclimatization in the chamber. The preparation was continuously perfused with ACSF (25 ml/min, in mM: 126 NaCl, 24 NaHCO3, 10 glucose, 4.5 KCl, 2 MgSO4, 1.25 NaH2PO4, and 2 CaCl2, pH 7.4, with 95% O2/5% CO2) via a gravity-fed perfusion system and maintained at 30°C. Local field potentials were recorded using glass micropipettes (2 - 6 MΩ) filled with ACSF. Signals were recorded through a differential AC amplifier (A-M Systems), filtered online (0.1 - 500 Hz), and sampled at 10 KHz. All drugs came from aliquots of stock solutions (stored at −70 °C) and were added to the perfusing artificial ACSF at the concentrations indicated. Pairwise comparisons between animals were performed with statistical analysis two sample t-test.
Results
Cholinergic agonist carbachol causes increase in the power of hippocampal theta activity
The effects of the cholinergic agonist carbachol in the hippocampal theta activity were investigated by adding 1 µM to our septo-hippocampal preparation with subsequent recording of the CA1 hippocampal area (Figure 1a). At baseline, the oscillations registered were in the range of theta band frequency, between 2 and 6 Hz (Figure 1a, 1b y 1c). During drug stimulation, the power of theta band activity increased as seen in the spectrogram analysis (Figure 1c). Filtered traces revealed the increment in theta power during stimulation (Figure 1b and 1c). The increase was further confirmed when the theta peak frequency was analyzed (Figure 1c and 1d). Interestingly, this increment in theta power was coupled to a reduction in theta frequency (Figure 1d). The behavior in frequency can be observed in the spectrogram analysis (Figure 1c) and the theta peak frequency analysis (Figure 1d). Statistical analysis revealed that cholinergic stimulation with carbachol induces a 129.55 +/-52.88 increase in the percentage of theta power (Figure 1e) and no significant change in the theta frequency (data not shown).
Cholinergic agonist carbachol at elevated concentrations (2 - 5 µM) elicited a decrease in power of hippocampal theta activity
Our data indicated increased power in theta activity with carbachol at concentrations of 1 µM (Figure 1). However, previous experiments were performed with carbachol between 5 and 10 µM [11]. In order to test this concentration in our septo-hippocampal preparation, we elevated carbachol concentration at higher doses (3 - 5 µM) (Figure 2a). Here, our data indicate a drastic decrease in theta power activity, as seen in raw traces and spectrogram analysis (Figure 2a and 2c). In order to investigate if the effect was mediated by muscarinic receptors, we applied scopolamine, an antagonist [10]. Changes in theta power were completely blocked by scopolamine addition (Figure 2b). The decrease is further confirmed when changes in theta peak power were analyzed (Figure 2d). Again, no detectable changes were observed in the frequency of the hippocampal theta activity (Figure 2c and 2d). Assuming, carbachol at elevated doses (5 µM) could be in the proximity of the saturated response, we decided to evaluate it at 3 µM. Here, our data indicate a similar effect in which the power of theta activity was decreased (data not shown). The statistical analysis confirmed our findings; carbachol at concentrations over 2 µM elicits a significant decrease in theta power activity (Figure 2e).
Carbachol at lower concentrations (0.2 to 0.5 µM) causes decrease in power of hippocampal theta activity
Our data indicated that carbachol at concentrations between 1 and 5 µM has an important effect on the power of hippocampal theta activity, increasing theta power at 1μM and decreasing it at concentrations over 2 µM (Figure 1 and 2). With this in mind, we decided to test carbachol concentrations under 1µM (0.2 to 0.5 µM). It should be noted that carbachol at concentrations of 0.5 µM have been tested using in-vitro experimental approaches [12,13]. Surprisingly, our data showed that this particular concentration reduces the power of the hippocampal theta activity, as seen in the raw traces and spectrogram analysis (Figure 3a, 3b and 3c). The filtered traces also confirm changes in power of theta activity during drug stimulation (Figure 3b). The reduction is further confirmed when changes in theta peak power were analyzed (Figure 3d). Again, no detectable changes were observed in the frequency of the hippocampal theta activity (Figure 3c). The statistical analysis confirms our findings, carbachol at concentrations lower than 1 μM causes a significant decrease in theta power activity (e).
Discussion
Is has previously been shown that there are two types of hippocampal theta activity, type I (atropine resistant or cholinergic independent) commonly associated with movement and, type II (atropine sensitive, cholinergic dependent) present when an animal is preparing to make movement [14,15]. In addition of being critical for integration of sensory information with motor output, theta activity has been correlated with spatial learning, navigation and is suggested to be critical for the induction of long term potentiation, a cellular mechanism of learning and memory [16]. Although theta activity can be seen in several brain structures, it is known that both types of theta activity can be strongly detected in the hippocampal formation [3]. Mechanistically, it was found that intraseptal microinfusion of carbachol resulted in continuous theta field activity regardless of what type of motor behaviour the animal performed or whether it was immobile [4]. Importantly, the performance of a voluntary movement resulted in an upward shift of theta frequency [4]. In contrariety, stimulation of cholinergic receptors in our septo-hippocampal preparation did not result in significant changes in theta frequency (Figure 1 and 2). In our case, the main difference was that we do not have all the inputs from another brain region i.e. entorhinal cortex, therefore our data contributes to dissecting the specific contribution of the septo-cholinergic pathway. Another important finding of intraseptal microinfusion of carbachol revealed enhancement of the hippocampal theta band [4]. This data has also been recently confirmed by Buszaky’s group [7]. In agreement with this data, our cholinergic stimulation with carbachol at 1 μM resulted in a significant increase of hippocampal theta power (Figure 1). To rule out the possibility of unspecific responses, we blocked our effect with the antagonist scopolamine, and the observed changes in theta power were fully reversed (Figure 2).
Interestingly, when we used higher concentrations of carbachol (2 - 5 µM) our recorded theta activity was drastically reduced (Figure 2). Again, no significant change was observed in the frequency of hippocampal theta activity (Figure 2). Initially we felt our results were due to a potential saturation effect; therefore, we decided to lower the carbachol concentration (0.2 - 0.5 μM) (Figure 3). Again, we observed a reduction in the hippocampal theta power with no detectable change in frequency (Figure 3).
Our data indicate that the concentration of the cholinergic agonist carbachol directly impacts in a dose-dependent manner the power of hippocampal theta activity. In agreement with published data, direct activation of the septo-cholinergic pathway resulted in direct modulation of hippocampal theta power. Additionally our data indicate positive or negative modulation of theta power can be achieved by different concentrations of cholinergic agonists. This data is of particular interest if we take into consideration that pharmacological activation of acetylcholine receptors with different molecules is a current proposed therapeutic strategy towards improvement of cognition in schizophrenia and Alzheimer's disease [17]. With this in mind, our data showed that proper receptor characterization towards hippocampal theta effect is critical when using and designing drugs directed to acetylcholine modulation.